000276274 001__ 276274
000276274 005__ 20250209000731.0
000276274 0247_ $$2doi$$a10.1016/j.parkreldis.2024.107256
000276274 0247_ $$2pmid$$apmid:39794217
000276274 0247_ $$2ISSN$$a1353-8020
000276274 0247_ $$2ISSN$$a1873-5126
000276274 0247_ $$2altmetric$$aaltmetric:172534162
000276274 037__ $$aDZNE-2025-00253
000276274 041__ $$aEnglish
000276274 082__ $$a610
000276274 1001_ $$aEspay, Alberto J$$b0
000276274 245__ $$aThe α-synuclein seed amplification assay: Interpreting a test of Parkinson's pathology.
000276274 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000276274 3367_ $$2DRIVER$$aarticle
000276274 3367_ $$2DataCite$$aOutput Types/Journal article
000276274 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738751572_16407$$xReview Article
000276274 3367_ $$2BibTeX$$aARTICLE
000276274 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276274 3367_ $$00$$2EndNote$$aJournal Article
000276274 520__ $$aThe α-synuclein seed amplification assay (αSyn-SAA) sensitively detects Lewy pathology, the amyloid state of α-synuclein, in the cerebrospinal fluid (CSF) of patients with Parkinson's disease (PD). The αSyn-SAA harnesses the physics of seeding, whereby a superconcentrated solution of recombinant α-synuclein lowers the thermodynamic threshold (nucleation barrier) for aggregated α-synuclein to act as a nucleation catalyst ('seed') to trigger the precipitation (nucleation) of monomeric α-synuclein into pathology. This laboratory setup increases the signal for identifying a catalyst if one is present in the tissue examined. The result is binary: positive, meaning precipitation occurred, and a catalyst is present, or negative, meaning no precipitation, therefore no catalyst. Since protein precipitation via seeding can only occur at a concentration many-fold higher than the human brain, laboratory-elicited seeding does not mean human brain seeding. We suggest that a positive αSyn-SAA reveals the presence of pathological α-synuclein but not the underlying etiology for the precipitation of monomeric α-synuclein into its pathological form. Thus, a positive αSyn-SAA supports a clinical diagnosis of PD but cannot inform disease pathogenesis, ascertain severity, predict the rate of progression, define biology or biological subtypes, or monitor treatment response.
000276274 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000276274 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276274 650_7 $$2Other$$aParkinson's disease
000276274 650_7 $$2Other$$aSeed amplification assay
000276274 650_7 $$2Other$$aSeeding
000276274 650_7 $$2Other$$aα-synuclein
000276274 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000276274 650_2 $$2MeSH$$aalpha-Synuclein: cerebrospinal fluid
000276274 650_2 $$2MeSH$$aalpha-Synuclein: metabolism
000276274 650_2 $$2MeSH$$aHumans
000276274 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000276274 650_2 $$2MeSH$$aParkinson Disease: cerebrospinal fluid
000276274 650_2 $$2MeSH$$aParkinson Disease: metabolism
000276274 7001_ $$aLees, Andrew J$$b1
000276274 7001_ $$aCardoso, Francisco$$b2
000276274 7001_ $$aFrucht, Steven J$$b3
000276274 7001_ $$aErskine, Daniel$$b4
000276274 7001_ $$aSandoval, Ivette M$$b5
000276274 7001_ $$aBernal-Conde, Luis Daniel$$b6
000276274 7001_ $$aSturchio, Andrea$$b7
000276274 7001_ $$aImarisio, Alberto$$b8
000276274 7001_ $$0P:(DE-2719)9000582$$aHoffmann, Christian$$b9$$udzne
000276274 7001_ $$aMontemagno, Kora T$$b10
000276274 7001_ $$0P:(DE-2719)9000670$$aMilovanovic, Dragomir$$b11$$udzne
000276274 7001_ $$aHalliday, Glenda M$$b12
000276274 7001_ $$aManfredsson, Fredric P$$b13
000276274 773__ $$0PERI:(DE-600)2027635-7$$a10.1016/j.parkreldis.2024.107256$$gVol. 131, p. 107256 -$$p107256$$tParkinsonism & related disorders$$v131$$x1353-8020$$y2025
000276274 8564_ $$uhttps://pub.dzne.de/record/276274/files/DZNE-2025-00253_Restricted.pdf
000276274 8564_ $$uhttps://pub.dzne.de/record/276274/files/DZNE-2025-00253_Restricted.pdf?subformat=pdfa$$xpdfa
000276274 909CO $$ooai:pub.dzne.de:276274$$pVDB
000276274 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000582$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000276274 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000670$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000276274 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000276274 9141_ $$y2025
000276274 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000276274 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000276274 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000276274 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000276274 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000276274 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000276274 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000276274 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPARKINSONISM RELAT D : 2022$$d2025-01-07
000276274 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000276274 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000276274 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000276274 9201_ $$0I:(DE-2719)1813002$$kAG Milovanovic (Berlin)$$lMolecular Neuroscience$$x0
000276274 980__ $$ajournal
000276274 980__ $$aVDB
000276274 980__ $$aI:(DE-2719)1813002
000276274 980__ $$aUNRESTRICTED